Categories for Drug Litigation

The Pradaxa lawsuit has inspired the lawsuits against Xarelto’s manufacturer for similar injuries sustained. Both drugs were designed, developed, and marketed as better alternatives to Coumedin. The main benefit was eliminating the requirement of constant blood tests which was both time-consuming and annoying for patients. Since both drugs were created, internal bleeding and even death have occurred among users. Lawsuits by both users of the...

read more

Pradaxa patients may have a better chance of surviving emergency surgeries, due to a recent study using 5g of idarucizumab (humanized antibody fragments). In critical cases, such as patients with uncontrolled bleeding, intracranial hemorrhage, or severe trauma following an automobile accident, there is a marginally improved chance for the patient to survive invasive procedures. The specific study mentioned that the timing of the treatment is crucial, such...

read more

Additional lawsuits filed this year in Ohio and Pennsylvania allege that the blood thinner drug Xarelto is causing serious injuries and death to patients nationwide. Xarelto has been proven to cause complications, such as: excessive bleeding, red or black stools, frequent nosebleeds, pink or brown urine, unexplained bruises, bruises that increase in size, coughing up blood or blood clots, vomiting blood or vomit that resembles...

read more

Four trial dates are set for early 2017 for the consolidated multidistrict litigation (MDL) against Bayer AG and a Johnson and Johnson subsidiary regarding injuries sustained by Xarelto patients. U.S. District Judge Eldon Fallon in the Eastern District of Louisiana issued the order for trial dates of February 6, 2017 and March 13, 2017. Mississippi’s Xarelto trials will be held on April 24, 2017. In...

read more

Many Xarelto lawsuits that have been filed against Johnson & Johnson and Bayer Corporation allege that the pharmaceutical companies failed to disclose the reality of the blood thinner’s risks and dangers. Xarelto has been prescribed as a blood thinner to treat many conditions, from nonvalvular atrial fibrillation, deep vein thrombosis, to pulmonary embolism. The favorable studies that center on the drug’s positive outcomes are also...

read more

Although there is still no antidote for Xarelto or Eliquis, the European Medicines Agency (EMA) is fast-tracking Praxbind as an antidote for the blood thinner Pradaxa. Pradaxa patients have been injured and dying due to the anticoagulant causing uncontrollable bleeding in emergencies. The life-threatening risk of uncontrolled bleeding is a constant threat to Pradaxa patients. The Committee for Medicinial Products for Human Use (CHMP) recommended...

read more

Last month, Huffington Post published a 58,000 word series on Johnson & Johnson’s illegal marketing of the dangerous drug Risperdal. Risperdal is proven to cause young boys to grow large breasts. The series exposes unethical and illegal behavior from Johnson and Johnson since Risperdal’s release in 1994. We can all take steps to ensure that Johnson & Johnson is accountable for manufacturing and selling dangerous drugs....

read more

Jasnssen Pharmaceuticals, Inc. published a recent study on the safety of Xarelto, where the drug manufacturer attempted to minimize the injuries and uncontrolled bleeding that Xarelto patients are suffering globally. Over 45,000 patients participated in the study. Janssen and the marketing firm that assisted with the study concluded that almost 3 out of 100 Xarelto patients experienced major bleeding. Our reports show that the issues with bleeding...

read more

The Washington Post published an article recently reporting concerns that the FDA did not adequately review the safety and risks of the Pradaxa blood thinner. Reports of Pradaxa injuries are coming in daily to our office, including an Indiana man who has been taking Pradaxa since 2013, and now has blood in his urine, a Vermont woman who took Pradaxa since 2011 and now has internal bleeding,...

read more

Pradaxa is a prescription blood thinner medicine that lowers the chance of blood clots forming in your body. It is commonly prescribed to reduce the risk of stroke and blood clots in patients with Atrial Fibrillation that is not caused by a heart valve problem. Pradaxa is also used to treat blood clots in the veins of the legs (Deep vein thrombosis, or DVT) or lungs (Pulmonary...

read more

Huffington Post has published “The Miracle Industry Series,” where the news outlet reveals that Johnson & Johnson spent 20 years marketing the drug Risperdal to children and the elderly. Once again, pharmaceutical profits won out over safety and the truth about the side effects. Huffington Post reveals that Johnson & Johnson’s “strategies, tactics, and mindset should make us wonder about the prescription drugs that are...

read more

Although the U.S. FDA approved Xarelto in 2011, many patients have experienced liver injuries and uncontrolled bleeding, resulting in severe damage and even death in some cases. In August, 2015, Canadian regulators announced an official investigation into numerous reports of liver injuries due to Xarelto use. The report states, “This issue was identified after two publications in the scientific literature described liver injury linked to the use...

read more

 Dr. Joseph Murray of the May Clinic has linked the condition sprue-like enteropathy to Benicar, a medication for high blood pressure. The list of symptoms and side effects related to Benicar use is growing. The small intestine can become damaged to the point where it cannot absorb nutrients effectively after Benicar use. Next, chronic diarrhea sets in, and kidney damage. Even more troubling, Benicar use can lead...

read more

Xarelto, the blockbuster anticoagulant that was approved by the FDA in 2011, has continued to come under scrutiny by parts of the medical community. Initially, the drug was approved to help reduce the risk of blood clots in patients who had undergone knee or hip replacement. Later, Xarelto was approved to help patients with deep vein thrombosis (DVT) and pulmonary embolism. Unfortunately, hundreds of patients...

read more

MISSION HILLS, CA – Sean David Pulskamp died tragically after taking Xarelto for three months. The cause of death was listed as cardiopulmonary arrest, pulmonary embolism, deep vein thrombosis, and pulmonary hypertension. Mr. Pulskamp was only 19 years old. Growing concerns over deaths and complications from blood thinners like Xarelto are forcing leading cardiologists to reconsider prescribing them. These risks and trends should not be...

read more

A new generation of anticoagulants, namely Xarelto and Pradaxa, have been at the center of much controversy in recent times. The manufacturers of these drugs have seen a significant increase in sales of their drugs, thanks in part to how convenient they are compared to more traditional blood thinners. However, the significant sales of these drugs can also be linked to Gregory Lip, a British heart...

read more

Since December 2014, all federal Xarelto lawsuits have been consolidated in the Eastern District of Louisiana. Any federal lawsuits filed against Janssen Pharmaceuticals and Bayer AG, the manufacturers of Xarelto (rivaroxaban), would have been transferred to the Louisiana court for pre-trial proceedings. By moving all cases into one court, federal judges expect to increase efficiency by all parties involved. Plaintiffs who have brought forth lawsuits...

read more

In the recent June 2015 issue of JAMA Ophthalmology, researchers studied some of Xarelto’s disturbing side effects, further calling into question the safety of the drug. These scientists studied the link between Xarelto usage and the possibility of an increase in stomach bleeds and eye hemorrhaging. Drs. Judy H. Hun and John C. Hwang found that patients in their 70s and 80s who had taken Xarelto after...

read more

A new experimental drug has been proven to reverse the effects of the drug Pradaxa (dabigatran). The drug, called idarucizumab, is said to work within minutes of being given to patients. Pradaxa is a newer anticoagulant that has been marketed as an easier alternative to traditional blood thinners. Unfortunately, it was not created alongside an antidote that could undo the potentially deadly side effects that...

read more

A recent study has revealed that mothers who take Xarelto can pass down the drug to their unborn child. When ingested during pregnancy, the anticoagulant transfers back and forth across the placenta between a mother and her fetus. The study was done by a research team at The Motherisk Program at the Hospital for Sick Children in Toronto and published most recently in the American...

read more

Xarelto, the blockbuster anticoagulant that was approved by the FDA in 2011, has recently seen an increase in sales even as the drug continues to cause problems for a significant number of patients. In the first quarter of 2015, both Xarelto sales and J& J pharmaceutical division sales increased by 3% to $7.7 billion. Bayer has increased its forecast for Xarelto’s 2015 sales growth to...

read more

Xarelto, a relatively new prescription blood thinner, was first approved by the FDA in 2011 for patients who were at risk of developing blood clots as a result of knee or hip replacement surgeries. The marketers of the anticoagulant, Janssen Pharmaceuticals, aggressively marketed the drug as a “one-size-fits-all” drug. Given that, doctors readily prescribed the drug because it didn’t require them to monitor their patients...

read more

Foreign regulators in Australia are questioning whether additional blood monitoring on new anticoagulants would make the drugs safer. These drugs include Pradaxa, Eliquis and more specifically, Xarelto. The Australian Therapeutic Goods Administration recently announced this month that it had completed a review of new oral anticoagulants like Xarelto and have concluded that regular blood monitoring would not improve the drugs. The group came to this...

read more

According to a new study published recently by the Johns Hopkins Bloomberg School of Public Health and George Washington University, Xarelto, along with Pradaxa, may pose an increased risk of gastrointestinal bleeding in patients. Patients who instead choose to take warfarin, an older anticoagulant, appear to have a decreased change of experiencing these side effects. The study followed 46,000 patients that were given either Pardaxa,...

read more

This year has seen a significant increase in the number of law suits being brought against the manufacturers of Xarelto, Johnson & Johnson and Bayer Corp.. Individuals and their families allege that they have faced harmful negative side effects after taking the drug and that Johnson & Johnson and Bayer knew this, but still aggressively marketed their blockbuster drug to consumers. Dozens so far have...

read more

When Xarelto was first introduced to the general pharmaceutical company, it was touted as a much more convenient alternative to traditional blood thinners like warfarin. The drug was originally prescribed to patients who had undergone knee and hip replacement surgery and who were at a higher risk of blood clots following those procedures. The advantage, Bayer Healthcare claimed, was that patients would not have to...

read more

Bayer, the manufacturer of the blockbuster anticoagulant drug, Xarelto, is not only facing a significant number of lawsuits within the United States, but also abroad in other countries. Recently, a number of Canadian citizens have filed claims against Bayer, either on their own behalf or that of deceased family members. According to Toronto lawyer Bryan McPhadden, his firm has filed a lawsuit for the family...

read more

In 2012, Reuters published a piece that touched on the hesitancy that some doctors felt about a new generation of blood thinners, one of which was Xarelto. In 2011, the FDA had approved Xarelto for prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip or knee replacement surgeries. A few months later, in November of 2011, the FDA approved it for a second use, for...

read more

In the March issue of the medical journal Academic Emergency Medicine, researchers from around the world found a disturbing correlation between the incidence of Xarelto-related bleeding in patients who are already at a higher risk for pulmonary embolism (PE). The study, sponsored by the manufacturers of Xarelto, Bayer HealthCare and Janssen, included about 5,000 patients at risk of pulmonary embolism. What they found was that...

read more

When Xarelto was first introduced to the market, doctors were quick to prescribe the medication because unlike it’s competition, warfarin, it didn’t require as much subsequent monitoring by the prescribing doctor. Now, as more individuals come forward and bring new civil law suits against its manufacturer, Bayer and Johnson & Johnson, doctors are become more reluctant to prescribe Xarelto. Both Xarelto and warfarin are anticoagulants...

read more

After Questcor, the pharmaceutical company behind Acthar, was acquired by Ireland’s Mallinckrodt, many questions began to be raised about the drug. One was the amount of money that Medicare has been paying for Acthar. In 2008, Medicare covered $141.5 million for the drug and in 2012, it covered around $220 million, increasing by almost double in just four years. Furthermore, in 2012, Medicare accounted for...

read more

Last month, it was made known that Bayer and Johnson & Johnson, the companies responsible for manufacturing the blood thinner Xarelto, are pushing for additional FDA approvals for their drug. Xarelto is already being prescribed to patients to treat blood clots, such as deep-vein thrombosis (DVT) and pulmonary embolus (PE), that occur more frequently in patients who have had certain types of surgeries, like knee...

read more

The American College of Obstetricians and Gynecologists recently released an article titled "What is New in the Use of Mesh in Vaginal Surgery?", which touched on some of the lingering effects that transvaginal mesh can have for women. One of the issues that the article also described was that of women who have remaining pain, even after troubling or painful mesh is removed. They state,...

read more

Recently, a judge found Ethicon, a division of Johnson & Johnson, liable for injuries that their Transvaginal Mesh Tape (TVT) Abbrevo caused one patient. The woman, identified as Coleen Perry, has been awarded $700,000 in compensatory damages and $5 million in punitive damages. The jury that was chosen to preside over the case deliberated for three days before reaching a verdict.  The plaintiff in this...

read more

Acthar, an expensive specialty drug prescribed to patients with various auto-immune and neurological diseases, has come under scrutiny in recent times for its severe and potentially deadly side effects. It’s also recently coming under more criticism because of the relationship many doctors have with its manufacturer, Questcor.  In 2012 alone, for example, 18 practitioners wrote 15 or more prescriptions for Acthar. At least 9 of...

read more

In February, Johnson & Johnson, one of the manufacturers of a TVM (transvaginal mesh) device, settled more than 100 lawsuits brought against them by consumer who had been hurt by the device. These particular cases were related to their Mentor unit manufactured transvaginal mesh tape and sling mesh devices.This particular mesh was discontinued in 2006, although Johnson & Johnson continues to allege that their device...

read more

Xarelto is one of the newest blood thinners on the market. It is prescribed to treat patients who are at risk of developing blood clots. However, Xarelto has recently received negative feedback from the pharmaceutical world because of its various side effects, the most common and most negative of them being an increased risk of internal bleeding. Patients who have brought civil lawsuits against the...

read more

Acthar is a prescription gel given to a wide variety of patients who suffer from different ailments. Among them are people with lupus, infants who suffer from infantile spasms, adults who are diagnosed with multiple sclerosis, and for other patients who deal with flares related to various other immune-related disorders. In July of 2014, the manufacturers of Acthar, Questcor Pharmaceuticals, submitted a regulatory filing that...

read more

It was recently announced that Bayer and Johnson & Johnson, the manufacturers of Xarelto, will continue to pursue additional FDA approvals for the drug, only this time, for stroke patients. Even as the two manufacturers continue to be hit with lawsuits by consumers who have been injured by the drug, they continue to pursue permission to market the drug for off-label use. Considering that there...

read more

On February 9th, 2015, JAMA Internal Medicine published an article stating that although the U.S. Food and Drug Administration (FDA) frequently finds problems with the way in which clinical sites perform biomedical research on human participants, this information is hardly ever distributed properly or adequately addressed when trials are published. Scientists who run these trials may be failing to adhere to good clinical practices and...

read more

CONTACT US

Use the form below to send us a note, call us at 214.890.0711 or chat with us live. We are eager to help with all your legal needs. Please keep in mind that any unsolicited information sent through our website cannot be treated as confidential. Contacting us through this site does not create a representation relationship with Fears | Nachawati.

Inquiry Type

  • General
  • Personal Injury
  • Immigration
  • Bankruptcy
  • Drug Litigation
  • Family Law

Locations

With offices in Texas, Florida and Colorado and attorneys licensed in Texas, Florida, Colorado, Arkansas and Oklahoma, Fears | Nachawati is dedicated to attaining the best possible solutions for our clients’ business and personal needs. We strive to be professionals who are creative, empathetic and reliable.

All Areas Served

We Can Help

Contact Fears Nachawati today

Free Consulation

Live Chat (Online Now)